Stellar Biotechnologies recently posted its presentation
from the Annual Meeting of the American Association of Immunologists to its
corporate website. The poster presentation, entitled Measuring the Properties
of Different Forms of Keyhole Limpet Hemocyanin (KLH) Reveals Important
Differences, was authored by scientists Shuguang Bi, Ph.D., Laura Milbrandt and
Catherine Brisson, Ph.D. The presentation highlights significant results from
the company’s research studies on the immunogenicity of different forms and
preparations of KLH.
KLH has been shown as an effective solution to stimulate
anti-tumor immune responses that can destroy tumor cells and, as a result, is
an active pharmaceutical ingredient in many new immunotherapies. This, along
with the rapidly expanding interest in therapeutic vaccines for cancer, has
created a significant biopharmaceutical market for KLH formulations. As an
industry leader in the sustainable manufacture of KLH, Stellar outlined the
significantly different properties found among different preparations of the
protein. Through its studies, the company concluded that both subunit KLH
(suKLH) and high molecular weight KLH (HMW KLH) have potential to be used as
effective antigen carriers.
“We know that different forms of KLH can elicit different
immune responses, so we are developing test methods to identify the suitable
form of KLH for any given application,” stated Dr. Catherine Brisson, chief
operating officer at Stellar. “Our goal is to improve the predictive outcome
when using KLH as an immunotherapy vaccine carrier or diagnostic immunogen,
whether in clinical or research applications.”
Currently, the valued protein is harvested exclusively from
the giant keyhole limpet, a scarce marine mollusk naturally found in the rocky
shallows along a limited stretch of the Pacific coastline extending from
Monterey Bay, California, to Isla Asuncion, near Baja California. Using
proprietary methods, facilities and technologies, Stellar is committed to
meeting the growing commercial-scale demand for the protein, providing the
company with unrivalled access to one of the industry’s most promising new
prospects.
According to the National Cancer Institute, there are
currently only two cancer vaccines approved for use in the United States, both
designed to protect against infection by the two types of human papillomavirus
(HPV) that are most commonly linked to cervical cancer. Since the introduction
of these vaccines in 2006, the CDC reports that HPV prevalence has decreased by
56% among female teenagers. These promising results have increased the focus on
potentially life-saving vaccines within the industry.
With a proprietary system for the development of KLH and
increasingly definitive studies on the protein’s specific effects, Stellar is
in a strong position to capitalize on its existing advantage moving forward.
Look for the company to have a substantial impact on the pharmaceutical
industry in the years to come.
For more information, visit www.stellarbiotech.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment